×
Vaxxinity Total Assets 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Vaxxinity total assets from 2020 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
View More
Vaxxinity Total Assets 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Vaxxinity total assets from 2020 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$153.4B
Gilead Sciences (GILD)
$121.1B
Bristol Myers Squibb (BMY)
$119.6B
Vertex Pharmaceuticals (VRTX)
$118.9B
CSL (CSLLY)
$83.5B
Regeneron Pharmaceuticals (REGN)
$74B
GSK (GSK)
$73.1B
Argenex SE (ARGX)
$39.8B
Alnylam Pharmaceuticals (ALNY)
$35B
BioNTech SE (BNTX)
$29.7B
BeiGene (ONC)
$22B
Illumina (ILMN)
$21.1B
Biogen (BIIB)
$21B
Moderna (MRNA)
$15.2B
Incyte (INCY)
$14.3B
Insmed (INSM)
$13.7B
Intra-Cellular Therapies (ITCI)
$13.5B
Genmab (GNMSF)
$13B
Genmab (GMAB)
$13B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.7B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.9B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Exact Sciences (EXAS)
$10.4B
Bio-Rad Laboratories (BIO.B)
$10B
QIAGEN (QGEN)
$9.9B
Exelixis (EXEL)
$9.5B
Repligen (RGEN)
$9.3B
Roivant Sciences (ROIV)
$8.1B